{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:40:13Z","timestamp":1783474813934,"version":"3.55.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Slow-release 4-aminopyridine (fampridine) has been shown to improve walking function in people with multiple sclerosis (MS). Its effect on other MS symptoms, such as fatigue, remains controversial. We performed this systematic review to summarize the evidence of the effect of fampridine on fatigue in patients with MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Scopus, EMBASE, Web of Science, google scholar, and ProQuest were searched for randomized trials or observational studies reporting fatigue scores before and after the treatment with fampridine. We summarized the findings of all relevant reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A literature search revealed 2,675 records; after removing duplicates, we had 1,504 records. Ninety-seven full texts were evaluated, and finally, 33 studies remained for systematic review. Most studies were done in USA, France, Germany, and Italy. The participants\u2019 age and the duration of studies ranged between 39 and 54\u202fyears and 2 and 48\u202fweeks, respectively. Out of 20 non-randomized or observational studies, 19 reported a benefit of fampridine in improving MS fatigue; however, only three out of 13 randomized, placebo-controlled studies showed that fampridine improved fatigue better than a placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overwhelmingly positive results of fampridine on fatigue reported in non-randomized and observational studies are compatible with the placebo-responsiveness of fatigue in MS. Randomized, placebo-controlled studies have provided inconsistent results on the effects of fampridine on MS fatigue. Although it is possible that fatigue, at least in a subgroup of people with MS, might respond to fampridine, high-quality, placebo-controlled, blinded, randomized trials are needed to show the efficacy of this medication in improving MS fatigue.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1720316","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:45:29Z","timestamp":1768833929000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The effects of fampridine on MS-related fatigue: a systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"Mohsen","family":"Rastkar","sequence":"first","affiliation":[{"name":"Student\u2019s Scientific Research Center, Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Cordano","sequence":"additional","affiliation":[{"name":"UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Ghajarzadeh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bardia","family":"Nourbakhsh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"ref1","first-page":"244","article-title":"Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis","author":"Ghajarzadeh","year":"2012"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13760-013-0198-2","article-title":"Fatigue in multiple sclerosis: relationship with disease duration, physical disability, disease pattern, age and sex","volume":"113","author":"Ghajarzadeh","year":"2013","journal-title":"Acta Neurol Belg"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-61076-1","article-title":"Fatigue profiles in patients with multiple sclerosis are based on severity of fatigue and not on dimensions of fatigue","volume":"10","author":"Beckerman","year":"2020","journal-title":"Sci Rep"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.clinph.2009.12.013","article-title":"Fatigue in multiple sclerosis: mechanisms and management","volume":"121","author":"Vucic","year":"2010","journal-title":"Clin Neurophysiol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jns.2010.12.008","article-title":"Sleep disorders and fatigue in multiple sclerosis: evidence for association and interaction","volume":"302","author":"Kaminska","year":"2011","journal-title":"J Neurol Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3389\/fneur.2017.00740","article-title":"Sleep-disordered breathing in people with multiple sclerosis: prevalence, pathophysiological mechanisms, and disease consequences","volume":"8","author":"Hensen","year":"2018","journal-title":"Front Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13023-021-01694-8","article-title":"Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials","volume":"16","author":"Zhang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1007\/s00415-018-8796-9","article-title":"Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years","volume":"265","author":"Broicher","year":"2018","journal-title":"J Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance","volume":"355","author":"J\u00fcni","year":"2016","journal-title":"Br Med J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13760-013-0198-2","article-title":"Fatigue in multiple sclerosis: relationship with disease duration, physical disability, disease pattern, age and sex","volume":"113","author":"Ghajarzadeh","year":"2013","journal-title":"Acta Neurol Belg"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.pmr.2005.01.014","article-title":"Multiple sclerosis\u2013related fatigue","volume":"16","author":"MacAllister","year":"2005","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/1545968306298934","article-title":"Origin of fatigue in multiple sclerosis: review of the literature","volume":"22","author":"Kos","year":"2008","journal-title":"Neurorehabil Neural Repair"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1136\/jnnp-2018-320050","article-title":"Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis","volume":"90","author":"Manjaly","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1177\/1352458521996002","article-title":"Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis","volume":"27","author":"Harrison","year":"2021","journal-title":"Mult Scler J"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(20)30354-9","article-title":"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial","volume":"20","author":"Nourbakhsh","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1113\/jphysiol.1981.sp013666","article-title":"The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres","volume":"313","author":"Bostock","year":"1981","journal-title":"J Physiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jns.2015.06.008","article-title":"Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders","volume":"356","author":"Lo","year":"2015","journal-title":"J Neurol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1007\/s00415-023-11858-0","article-title":"Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine","volume":"270","author":"Rocca","year":"2023","journal-title":"J Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1111\/ene.14867","article-title":"Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine","volume":"28","author":"Rocca","year":"2021","journal-title":"Eur J Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1720316\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:36:52Z","timestamp":1771918612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1720316\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":21,"alternative-id":["10.3389\/fneur.2025.1720316"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1720316","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"article-number":"1720316"}}